RESUMEN
Objective To evaluate the clinical efficacy of Yiqi Fumai and Zixin Yangyin Prescription combined with Captopril for the treatment of children's hand-foot-mouth disease (HFMD) complicated with viral myocarditis (VMC); To explore the mechanism. Methods Totally 80 cases children with HFMD complicated with VMC were selected and randomly divided into two groups, with 40 cases in each group. Both groups were given conventional low flow oxygen, cardiac function monitoring, ribavirin antiviral, and fructose nutrition, and severe cases were given immune globulin and dexamethasone to relieve symptoms. The control group was given Captopril 0.5 mg/(kg?d), three times a day,orally,on the basis of conventional treatment,and the treatment group was given Yiqi Fumai and Zixin Yangyin Prescription on the basis of control group,one dose a day,decoction 180 mL,6 to 10 times a day,orally. The treatment in both groups lasted for two weeks. Serum hs-CRP, CK, CK-MB and cardiac function change before and after treatment of the two groups were observed. Electrocardiogram curative effect and comprehensive curative effect were evaluated. Results Compared with before treatment, the contents of hs-CRP, CK-MB, and CK in both groups decreased after treatment (P<0.05), and the treatment group was lower than the control group (P<0.05);Compared with before treatment, EF and FS in both groups increased after treatment, and A/E of mitral valve diastolic blood flow velocity peak decreased after treatment, with statistical significance among EF, FS and A/E between the two groups (P<0.05). The total effective rate of electrocardiogram was 92.5% (37/40) in the treatment group and 75.0% (30/40) in the control group, with statistical significance (Z=-2.370, P=0.018). The total effective rate of comprehensive efficacy was 92.5% (37/40) in the treatment group, and 77.5% (31/40) in the control group, with statistical significance (Z=-2.397, P=0.017). Conclusion Yiqi Fumai and Zixin Yangyin Prescription combined with Captopril can improve the clinical symptoms of HFMD complicated with VMC, improve clinical efficacy, whose mechanism may be related to the decrease of contents of hs-CRP, CK and CK-MB and enhancement of cardiac function.
RESUMEN
Objective To evaluate the clinical efficacy of Yiqi Fumai and Zixin Yangyin Prescription combined with Captopril for the treatment of children's hand-foot-mouth disease (HFMD) complicated with viral myocarditis (VMC); To explore the mechanism. Methods Totally 80 cases children with HFMD complicated with VMC were selected and randomly divided into two groups, with 40 cases in each group. Both groups were given conventional low flow oxygen, cardiac function monitoring, ribavirin antiviral, and fructose nutrition, and severe cases were given immune globulin and dexamethasone to relieve symptoms. The control group was given Captopril 0.5 mg/(kg?d), three times a day,orally,on the basis of conventional treatment,and the treatment group was given Yiqi Fumai and Zixin Yangyin Prescription on the basis of control group,one dose a day,decoction 180 mL,6 to 10 times a day,orally. The treatment in both groups lasted for two weeks. Serum hs-CRP, CK, CK-MB and cardiac function change before and after treatment of the two groups were observed. Electrocardiogram curative effect and comprehensive curative effect were evaluated. Results Compared with before treatment, the contents of hs-CRP, CK-MB, and CK in both groups decreased after treatment (P<0.05), and the treatment group was lower than the control group (P<0.05);Compared with before treatment, EF and FS in both groups increased after treatment, and A/E of mitral valve diastolic blood flow velocity peak decreased after treatment, with statistical significance among EF, FS and A/E between the two groups (P<0.05). The total effective rate of electrocardiogram was 92.5% (37/40) in the treatment group and 75.0% (30/40) in the control group, with statistical significance (Z=-2.370, P=0.018). The total effective rate of comprehensive efficacy was 92.5% (37/40) in the treatment group, and 77.5% (31/40) in the control group, with statistical significance (Z=-2.397, P=0.017). Conclusion Yiqi Fumai and Zixin Yangyin Prescription combined with Captopril can improve the clinical symptoms of HFMD complicated with VMC, improve clinical efficacy, whose mechanism may be related to the decrease of contents of hs-CRP, CK and CK-MB and enhancement of cardiac function.
RESUMEN
Objective:To investigate the effect of NF-κB p65siRNA of IL-17 inducing the expression of MCP-1 in the primary cultured cardiac myocytes.Methods:The cardiac myocytes were isolated from neonatal mice by different adhesion method.NF-κB P65 siRNA was transfected into cardiac myocytes and the rates of transcription and translation of MCP-1 were detected by RT-PCR and enzyme-linked immunosorbent assay( ELISA) ,the rates of transcription and translation of P-P65 and P65 were detected by RT-PCR and Western blot.Results:Compared with negative siRNA group,the expression of the MCP-1 at mRNA and protein levels were increased in negative siRNA +IL-17 group(P0.05 ) .Conclusion: IL-17 stimulates MCP-1 expression in cardiac myocytes via NF-κB activation,and NF-κB P65 siRNA can effectively inhibit the upregulation of IL-17 on MCP-1.